Drugs / VEROSUDIL
VEROSUDIL
Trials 12 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01250197 | Nov → Dec 2010 | — | Aerie Pharmaceuticals | Completed | No outcome recorded |
| Phase 211 trials | ||||||
| Phase 2 | NCT02174991 | Jun 2014 → Feb 2015 | glaucoma | New York Glaucoma Research Institute | Unknown | No outcome recorded |
| Phase 2 | NCT02173223 | Jun 2014 → Feb 2015 | glaucoma | New York Glaucoma Research Institute | Unknown | No outcome recorded |
| Phase 2 | NCT02152774 | May 2014 → Feb 2015 | chronic closed-angle glaucoma | New York Glaucoma Research Institute | Unknown | No outcome recorded |
| Phase 2 | NCT01936389 | Sep 2013 → Oct 2014 | exfoliation syndrome, ocular hypertension, open-angle glaucoma | Robert Ritch, MD, LLC. | Completed | No outcome recorded |
| Phase 2 | NCT01789736 | Feb → Jun 2013 | ocular hypertension, open-angle glaucoma | Aerie Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01699464 | Oct 2012 → Apr 2013 | ocular hypertension, open-angle glaucoma | Aerie Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01474135 | Dec 2011 → Apr 2012 | glaucoma, ocular hypertension | Aerie Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01330979 | May 2011 → Aug 2012 | ocular hypertension, open-angle glaucoma | Aerie Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01302249 | Feb → Dec 2011 | glaucoma, ocular hypertension | Aerie Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01060579 | Feb → Aug 2010 | glaucoma | Aerie Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00902200 | May → Sep 2009 | ocular hypertension | Aerie Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 14 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VEROSUDIL | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545065 ↗ |
| Known as | AR-12286 | “AR-12286 is a novel, potent Rho-kinase inhibitor developed by Aerie Pharmaceuticals, Inc., Bridgewater, NJ.” NCT02152774 ↗11“AR-12286 is a novel Rho-kinase inhibitor developed by Aerie Pharmaceuticals, Inc., Bridgewater, NJ.” NCT02173223 ↗ |
| Known as | AR-12286 FREE BASE | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545065 ↗ |
| Known as | VEROSUDIL HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545065 ↗ |
| Action | Inhibit | “Rho kinase inhibitor AR-12286” PMID 21794845 ↗ Jul 2011 |
| Modality | Small molecule | — CHEMBL3545065 ↗ |
| Route | Topical | “topical AR-12286” NCT01060579 ↗ |